Femasys (NASDAQ:FEMY) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Femasys (NASDAQ:FEMY) in a research report sent to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $12.00 price target on the stock.

Separately, Chardan Capital dropped their price target on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Femasys Stock Performance

FEMY opened at $1.65 on Wednesday. Femasys has a 1-year low of $0.86 and a 1-year high of $2.40. The stock has a market cap of $37.78 million, a P/E ratio of -2.04 and a beta of -2.81. The stock’s 50 day simple moving average is $1.22 and its 200 day simple moving average is $1.16. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of FEMY. Citadel Advisors LLC acquired a new stake in Femasys during the 4th quarter valued at $45,000. Northern Trust Corp lifted its position in shares of Femasys by 42.6% in the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock valued at $139,000 after acquiring an additional 37,675 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Femasys during the fourth quarter valued at $30,000. Aljian Capital Management LLC purchased a new stake in Femasys during the 3rd quarter worth about $27,000. Finally, Virtu Financial LLC acquired a new position in Femasys in the 4th quarter valued at about $25,000. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.